en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
1/2016
vol. 54
 
Share:
Share:
more
 
 
abstract:
Case report

Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease

Qasim Akram
,
Mark Roberts
,
Chester Oddis
,
Arianne Herrick
,
Hector Chinoy

Reumatologia 2016; 54, 1: 35–37
Online publish date: 2016/03/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease.We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.
keywords:

rituximab, myositis, systemic sclerosis, neutropenia







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.